EGFR and non-small cell lung carcinoma: An interesting new development is EXosome-focused Translational Research for Afatinib (EXTRA), a prospective study to identify novel predictive biomarkers and a resistance marker for the TKI afatinib in NSCLC patients that express mutant EGFR [233].